India, July 18 -- Novo Nordisk India has announced that the Central Drugs Standard Control Organization (CDSCO) has approved a new indication for Wegovy(R) (semaglutide injection 2.4 mg), making it the first and only GLP-1 receptor agonists (RA) to be approved both globally and in India for the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity.

MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage. Two in three Indians have fatty liver disease. It is a silent disease and people often do not have symptoms until the disease ...